{"id":2962,"date":"2023-10-07T17:41:53","date_gmt":"2023-10-07T21:41:53","guid":{"rendered":"https:\/\/immunebiosolutions.com\/?p=2962"},"modified":"2025-11-05T14:27:51","modified_gmt":"2025-11-05T19:27:51","slug":"safety-and-efficacy-of-inhaled-ibio123-for-severe-covid-19-a-randomised-double-blind-dose-ascending-placebo-controlled-phase-1-2-trial","status":"publish","type":"post","link":"https:\/\/immunebiosolutions.com\/en\/safety-and-efficacy-of-inhaled-ibio123-for-severe-covid-19-a-randomised-double-blind-dose-ascending-placebo-controlled-phase-1-2-trial\/","title":{"rendered":"Safety and efficacy of inhaled IBIO123 for severe COVID-19, new results."},"content":{"rendered":"\n<p>October 6, 2023<\/p>\n\n\n\n<p>Immune Biosolutions is pleased to share the most recent findings from our second Phase 1\/2 clinical trial (NCT05303376). This study focused on evaluating the safety and efficacy of repeated doses of IBIO123 in treating severe COVID-19 cases among recently hospitalized patients.<\/p>\n\n\n\n<p>Article available in preprint:<a href=\" https:\/\/papers.ssrn.com\/sol3\/papers.cfm?abstract_id=4593223\"> https:\/\/papers.ssrn.com\/sol3\/papers.cfm?abstract_id=4593223<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>October 6, 2023 Immune Biosolutions is pleased to share the most recent findings from our second Phase 1\/2 clinical trial&#8230;<\/p>\n","protected":false},"author":35,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_kad_blocks_custom_css":"","_kad_blocks_head_custom_js":"","_kad_blocks_body_custom_js":"","_kad_blocks_footer_custom_js":"","_kad_post_transparent":"","_kad_post_title":"","_kad_post_layout":"","_kad_post_sidebar_id":"","_kad_post_content_style":"","_kad_post_vertical_padding":"","_kad_post_feature":"","_kad_post_feature_position":"","_kad_post_header":false,"_kad_post_footer":false,"_kad_post_classname":"","footnotes":""},"categories":[15],"tags":[],"class_list":["post-2962","post","type-post","status-publish","format-standard","hentry","category-news"],"acf":[],"taxonomy_info":{"category":[{"value":15,"label":"News"}]},"featured_image_src_large":false,"author_info":{"display_name":"Laurence Tessier","author_link":"https:\/\/immunebiosolutions.com\/en\/author\/ltessieribiosolutions-com\/"},"comment_info":0,"category_info":[{"term_id":15,"name":"News","slug":"news","term_group":0,"term_taxonomy_id":15,"taxonomy":"category","description":"","parent":0,"count":21,"filter":"raw","cat_ID":15,"category_count":21,"category_description":"","cat_name":"News","category_nicename":"news","category_parent":0}],"tag_info":false,"_links":{"self":[{"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/posts\/2962","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/comments?post=2962"}],"version-history":[{"count":2,"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/posts\/2962\/revisions"}],"predecessor-version":[{"id":2966,"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/posts\/2962\/revisions\/2966"}],"wp:attachment":[{"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/media?parent=2962"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/categories?post=2962"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/tags?post=2962"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}